Ex­perts talk IRA im­pacts as CMS an­nounces it will pub­lish first 10 drugs up for ne­go­ti­a­tion in Sep­tem­ber

Ex­perts went back and forth on the im­pacts of the In­fla­tion Re­duc­tion Act, or IRA, on the bio­phar­ma in­dus­try in a vir­tu­al pan­el host­ed by End­points News at JP Mor­gan Wednes­day.

The ma­jor drug pric­ing re­form passed last year and al­lowed Medicare drug price ne­go­ti­a­tions for the first time ever. It al­so capped se­nior drug ex­pens­es at $2,000 a year and in­sulin costs at $35 a month.

Wednes­day morn­ing, the Cen­ters for Medicare & Med­ic­aid Ser­vices (CMS) an­nounced its time­line for ne­go­ti­a­tions. In a me­dia call, CMS ad­min­is­tra­tor Chiq­ui­ta Brooks-La­Sure said, “Our ac­tions this year will cul­mi­nate in the an­nounce­ment of a list of 10 part D, high-spend brand name drugs to par­tic­i­pate in the ne­go­ti­a­tion pro­gram.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER